ERA-NET TRANSCAN-2: Translational research on rare cancers

This call of TRANSCAN focuses on:  “Translational research on rare cancers”

The call has three specific aims, and proposals must cover at least one of the specific topics listed below:

1: Design and conduct of translational research studies exploiting/combining resources from current clinical trials, bio-repositories and epidemiology-type resources.

2: Development and exploitation of translational research platforms (e.g., patient derived xenograft models/organoids/tissue collections) to study drug responses/resistance and toxicity, and perform drug screens or repurpose approved anticancer drugs.

3: Implementation of precision biomarkers for better stratification of the clinical cohorts.

Israeli applicants should contact Chief Scientist of the Minsitry of Health (Dr. Irit Alon/ Dr. Ayelet Zamir) to review and approve submission prior to application. 

Pls. note that in most cases applicants may hold only one MOH grant at any given time. Please check eligibility.

Funding: €140,000 total for Israeli partner + €20,000 for coordination
Duration: 3 years

Research Authority due date: 1.2.18

Pre proposal due date: 6.2.18
Full proposal due date:  30.5.18